Evidence map›Paper›PMID 32390708›Full record

ArticleWorld journal of gastroenterology2020

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and

Apolonia Novillo, María Gaibar, Alicia Romero-Lorca, María Fuencisla Gilsanz, Laura Beltrán, Miguel Galán, Beatriz Antón, Diego Malón, Amalia Moreno, Ana Fernández-Santander

Open access · bronzeAbstract read
In one paragraph

Article in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Genetic Variants ofInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Apolonia NovilloDepartment of Pre-clinical Dentistry, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid 28670, Spain.
María GaibarDepartment of Health Sciences, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid 28670, Spain.
Alicia Romero-LorcaDepartment of Medicine, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid 28670, Spain.
María Fuencisla GilsanzDepartment of Medicine, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid 28670, Spain.
Laura BeltránDepartment of Health Sciences, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid 28670, Spain.
Miguel GalánDepartment of Health Sciences, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid 28670, Spain.
Beatriz AntónDepartment of Oncology, University Hospital of Fuenlabrada, Fuenlabrada, Madrid 28942, Spain.
Diego MalónDepartment of Oncology, University Hospital of Fuenlabrada, Fuenlabrada, Madrid 28942, Spain.
Amalia MorenoDepartment of Pathological Anatomy, University Hospital of Fuenlabrada, Fuenlabrada, Madrid 28942, Spain.
Ana Fernández-SantanderDepartment of Medicine, Health Sciences Faculty, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid 28670, Spain. ana.fernandez@universidadeuropea.es.
Universidad Europea de Madrid · ESHospital Universitario de Fuenlabrada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemokine CASE SUMMARY: We report six cases of stage IV KRAS-mutated mCRC. Patients were given first line treatment with BVZ-containing chemotherapy in University Hospital of Fuenlabrada. The six patients differed in terms of primary tumor location (right/left side), tumor burden (mostly hepatic and peritoneal disease) and clinical disease course. Before treatment onset, total RNA was isolated from paraffinated tumor biopsy specimens and

conclusionA higher expression of

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiopsyChemokine CXCL5Colorectal NeoplasmsDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisProgression-Free SurvivalBevacizumabChemokine CXCL5CXCL5 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)BevacizumabCase reportChemokine CXCL5Colorectal cancerGene expressionProgression-free survival

Identifiers

PMID32390708
PMCPMC7201148
OpenAlexW3020998435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.